Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants
Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
A phase 2 randomised, three-arm, parallel-group, dose-ranging trial to determine safety, efficacy and optimal dosing of intravenous anakinra in premature neonates, with subcutaneous pharmacokinetic sub-study.
Phase:
PHASE2
Details
Lead Sponsor:
Monash Medical Centre
Collaborators:
Hudson Institute of Medical Research Liggins Institute Monash University Starship Children's Hospital of New Zealand